Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Typ-2-Diabetes und Adipositas Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Häufige urologisch-sexualmedizinische Themen in der Praxis sind das Thema des MMW-Webinars am 5. Juni von 17.30 bis 19 Uhr. Konkret geht es um die Frage, wann bei Harnwegsinfektionen auf Antibiotika verzichtet werden kann, und um ein Update zur Therapie von Libido- und Potenzstörungen des Mannes. Der dritte Vortrag behandelt sexuell übertragbare Krankheiten. Stellen Sie Ihre Fragen an die Experten und sammeln Sie 2 CME-Punkte. Jetzt gleich anmelden!
Erweiterte Suche
Anmelden
nach oben
Clinical Research in Cardiology
Erschienen in: Clinical Research in Cardiology 10/2008

01.10.2008 | REVIEW

Cardiovascular protection for all individuals at high risk: evidence-based best practice

verfasst von: George Bakris, Michael Böhm, Gilles Dagenais, Hans-Christoph Diener, Toshiro Fujita, Philip Gorelick, Sverre Erik Kjeldsen, Markku Laakso, Giuseppe Mancia, Bertram Pitt, Arya Sharma, Peter Sleight, Koon Teo, Thomas Unger, Michael Weber, Bryan Williams, Faiez Zannad

Erschienen in: Clinical Research in Cardiology | Ausgabe 10/2008

Einloggen, um Zugang zu erhalten

Abstract

Patients with cardiovascular risk factors are largely undertreated, for many reasons. Vulnerable individuals may not be aware of the risks they are facing or an individual’s risk of cardiovascular disease may be underestimated, particularly among those at high risk. Furthermore, in individuals identified as being at high total cardiovascular risk, the full spectrum of therapeutic options may not be implemented or patients may not adhere to the treatment prescribed. We address these critical issues by summarizing the existing guidelines: our ultimate goal is to encourage the optimal management of individuals at high total cardiovascular risk according to evidence-based medicine, with the expectation that this will improve outcomes.
Literatur
1.
ADVANCE Collaborative Group (2007) Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial. Lancet 370:829–840CrossRef
2.
American Diabetes Association (2004) Aspirin therapy in diabetes. Dia Care 26:S87–S88
3.
Antithrombotic Trialists’ Collaboration (2002) Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 324:71–86CrossRef
4.
Backlund L, Bring J, Strender L-E (2004) How accurately do general practitioners and students estimate coronary risk in hypercholesterolaemic patients? Prim Health Care Res Dev 5:145–152CrossRef
5.
Balady GJ, Williams MA, Ades PA, Bittner V, Comoss P, Foody JM, Franklin B, Sanderson B, Southard D, American Heart Association Exercise, Cardiac Rehabilitation, Prevention Committee, the Council on Clinical Cardiology, American Heart Association Council on Cardiovascular Nursing; American Heart Association Council on Epidemiology and Prevention, American Heart Association Council on Nutrition, Physical Activity, and Metabolism; American Association of Cardiovascular and Pulmonary Rehabilitation (2007) Core components of cardiac rehabilitation/secondary prevention programs: 2007 update: a scientific statement from the American Heart Association Exercise, Cardiac Rehabilitation, and Prevention Committee, the Council on Clinical Cardiology; the Councils on cardiovascular nursing, epidemiology and prevention, and nutrition, physical activity, and metabolism; and the American Association of cardiovascular and pulmonary rehabilitation. Circulation 115:2675–2682
6.
Ballantyne CM (1998) Low-density lipoproteins and risk for coronary artery disease. Am J Cardiol 82:3Q–12QPubMedCrossRef
7.
Barrios V, Escobar C, Calderon A, Echarri R, González-Pedel V, Ruilope LM, CONTROLRISK Investigators (2007) Cardiovascular risk profile and risk stratification of the hypertensive population attended by general practitioners and specialists in Spain. The CONTROLRISK Study. J Hum Hypertens 21:479–485PubMed
8.
Barter P, Gotto AM, LaRosa JC, Maroni J, Szarek M, Grundy SM, Kastelein JJ, Bittner V, Fruchart JC, Treating to New Targets Investigators (2007) HDL cholesterol, very low levels of LDL cholesterol, and cardiovascular events. N Engl J Med 357:1301–1310PubMedCrossRef
9.
Bhatt DL, Fox KA, Hacke W, Berger PB, Black HR, Boden WE, Cacoub P, Cohen EA, Creager MA, Easton JD, Flather MD, Haffner SM, Hamm CW, Hankey GJ, Johnston SC, Mak KH, Mas JL, Montalescot G, Pearson TA, Steg PG, Steinhubl SR, Weber MA, Booth J, Topol EJ, CHARISMA Investigators (2005) A global view of atherothrombosis: baseline characteristics in the clopidogrel for high atherothrombotic risk and ischemic stabilization, management, and avoidance (CHARISMA) trial. Am Heart J 150:401.e1–401.e7CrossRef
10.
Bhatt DL, Fox KA, Hacke W, Berger PB, Black HR, Boden WE, Cacoub P, Cohen EA, Creager MA, Easton JD, Flather MD, Haffner SM, Hamm CW, Hankey GJ, Johnston SC, Mak KH, Mas JL, Montalescot G, Pearson TA, Steg PG, Steinhubl SR, Weber MA, Brennan DM, Fabry-Ribaudo L, Booth J, Topol EJ, CHARISMA Investigators (2006) Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. N Engl J Med 354:1706–1717PubMedCrossRef
11.
Blood Pressure Lowering Treatment Trialists’ Collaboration (2003) Effects of blood-pressure-lowering regimens on major cardiovascular events: results of prospectively-designed overviews of randomised trials. Lancet 362:1527–1535CrossRef
12.
Brindle P, Beswick A, Fahey T, Ebrahim S (2006) Accuracy and impact of risk assessment in the primary prevention of cardiovascular disease: a systematic review. Heart 92:1752–1759PubMedCrossRef
13.
CAPRIE Steering Committee (1996) A randomised, blinded trial of clodipogrel versus aspirin in patients at risk of ischemic events (CAPRIE). Lancet 348:1329–1339CrossRef
14.
Campbell NC, Thain J, Deans HG, Ritchie LD, Rawles JM, Squair JL (1998) Secondary prevention in coronary heart disease: baseline survey of provision in general practice. BMJ 316:1430–1434PubMed
15.
Carey MP, Maisto SA, Kalichman SC, Forsyth AD, Wright EM, Johnson BT (1997) Enhancing motivation to reduce the risk of HIV infection for economically disadvantaged urban women. J Consult Clin Psychol 65:531–541PubMedCrossRef
16.
Cholesterol Treatment Trialists’ (CTT) Collaboration (2005) Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 366:1267–1278CrossRef
17.
Claxton AJ, Cramer J, Pierce C (2001) A systematic review of the association between dose regimens and medication compliance. Clin Ther 23:1296–1310PubMedCrossRef
18.
Colhoun HM, Betteridge DJ, Durrington PN, Hitman GA, Neil HA, Livingstone SJ, Thomason MJ, Mackness MI, Charlton-Menys V, Fuller JH, CARDS Investigators (2004) Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the collaborative Atorvastatin diabetes study (CARDS): multicentre randomised placebo-controlled trial. Lancet 364:685–696PubMedCrossRef
19.
Collins R, Armitage J, Parish S, Sleight P, Peto R, Heart Protection Study Collaborative Group (2003) MRC/BHF heart protection study of cholesterol-lowering with simvastatin in 5,963 people with diabetes: a randomised placebo-controlled trial. Lancet 361:2005–2016PubMedCrossRef
20.
Critchley J, Capewell S (2004) Smoking cessation for the secondary prevention of coronary heart disease. Cochrane Database Syst Rev 1:CD003041PubMed
21.
Cuspidi C, Ambrosioni E, Mancia G, Pessina AC, Trimarco B, Zanchetti A, APROS Investigators (2002) Role of echocardiography and carotid ultrasonography in stratifying risk in patients with essential hypertension: the assessment of prognostic risk observational survey. J Hypertens 20:1307–1314PubMedCrossRef
22.
Dagenais GR, Pogue J, Fox K, Simoons ML, Yusuf S (2006) Angiotensin-converting-enzyme inhibitors in stable vascular disease without left ventricular systolic dysfunction or heart failure: a combined analysis of three trials. Lancet 368:581–588PubMedCrossRef
23.
De Schryver EL, Algra A, van Gijn J (2007) Dipyridamole for preventing stroke and other vascular events in patients with vascular disease. Cochrane Database Syst Rev 18(3):CD001820
24.
Devereux RB, Watchell K, Gerdts E, Boman K, Nieminen MS, Papademetriou V, Rokkedal J, Harris K, Aurup P, Dahlöf B (2004) Prognostic significance of left ventricular mass change during treatment of hypertension. JAMA 292:2350–2356PubMedCrossRef
25.
Di Castelnuovo A, Rotondo S, Iacoviello L, Donati MB, De Gaetano G (2002) Meta-analysis of wine and beer consumption in relation to vascular risk. Circulation 105:2836–2844PubMedCrossRef
26.
Diabetes Prevention Program Research Group (2002) Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 346:393–403CrossRef
27.
Diener HC, Bogousslavsky, Brass LM, Cimminiello C, Csiba L, Kaste M, Leys D, Matias-Guiu J, Rupprecht HJ, MATCH Investigators (2004) Aspirin and clopidogrel compared to clopidogrel alone after recent ischaemic stroke or transient ischaemic attack in high-risk patients (MATCH): randomized, double-blind, placebo controlled trial. Lancet 64:331–337CrossRef
28.
Diener HC, Cunha L, Forbes C, Sivenius J, Smets P, Lowenthal A (1996) European stroke prevention study 2: dipyridamole and acetylsalicylic acid in secondary prevention of stroke. J Neurol Sci 143:1–13PubMedCrossRef
29.
Diener HC, Sacco R, Yusuf S (2007) Rationale, design and baseline data of a randomized, double blind, controlled trial comparing two antithrombotic regimens (a fixed-dose combination of extended-release dipyridamole plus ASA with clopidogrel) and telmisartan versus placebo in patients with strokes: the prevention regimen for effectively avoiding second strokes trial (PRoFESS). Cerebrovasc Dis 23:368–380PubMedCrossRef
30.
Elmer PJ, Obarzanek E, Vollmer WM, Simons-Morton D, Stevens VJ, Young DR, Lin PH, Champagne C, Harsha DW, Svetkey LP, Ard J, Brantley PJ, Proschan MA, Erlinger TP, Appel LJ, PREMIER Collaborative Research Group (2006) Effects of comprehensive lifestyle modification on diet, weight, physical fitness, and blood pressure control: 18-month results of a randomized trial. Ann Intern Med 144:485–495PubMed
31.
Erhardt L (2005) Managing cardiovascular risk: reality Vs. perception. Eur Heart J 7(Suppl. L):L11–L15
32.
ESPRIT The Esprit Study Group (2006) Aspirin plus dipyridamole versus aspirin alone after cerebral ischaemia of arterial origin (ESPRIT): randomised controlled trial. Lancet 376:1665–1673
33.
EUROASPIRE II Study Group (2001) Lifestyle and risk factor management and use of drug therapies in coronary patients from 15 countries. Principal results from EUROASPIRE II Euro Heart Survey Programme. Eur Heart J 22:554–572CrossRef
34.
Finchham JE (1996) Advancing prescription medicine compliance: new paradigms, new practices. J Pharmcoepidemiol 3:37–48
35.
36.
Fisher JD, Fisher WA, Misovich SJ, Kimble DL, Malloy TE (1996) Changing AIDS risk behavior: effects of an intervention emphasizing AIDS risk reduction information, motivation, and behavioral skills in a college student population. Health Psychol 15:114–123PubMedCrossRef
37.
Garg R, Yusuf S (1995) Overview of randomized trials of angiotensin-converting enzyme inhibitors on mortality and morbidity in patients with heart failure. Collaborative Group on ace inhibitor trials. JAMA 273:1450–1456PubMedCrossRef
38.
Hansson L, Zanchetti A, Carruthers SG, Dahlöf B, Elmfeldt D, Julius S, Ménard J, Rahn KH, Wedel H, Westerling S (1998) Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the hypertension optimal treatment (HOT) randomised trial. Lancet 351:1755–1762PubMedCrossRef
39.
Harmon G, Lefante J, Krousel-Wood M (2006) Overcoming barriers: the role of providers in improving patient adherence to antihypertensive medications. Curr Opin Cardiol 21:310–315PubMedCrossRef
40.
Hart RG, Benavente O, McBride R, Pearce LA (1999) Antithrombotic therapy to prevent stroke in patients with atrial fibrillation: a meta-analysis. Ann Intern Med 131:492–501PubMed
41.
Heart Outcomes Prevention Evaluation (HOPE) Study Investigators (2000) Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO_HOPE substudy. Lancet 335:253–259
42.
Heart Outcomes Prevention Evaluation Study Investigators (2000) Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med 342:145–153CrossRef
43.
Heart Protection Study Collaborative Group (2002) MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 360:7–22CrossRef
44.
Hobbs FDR, Erhardt L (2002) Acceptance of guideline recommendations and perceived implementation of coronary heart disease prevention among primary care physicians in five European countries: the reassessing European attitudes about cardiovascular treatment (REACT) survey. Fam Pract 19:596–604PubMedCrossRef
45.
Houston MC (2002) The role of vascular biology, nutrition and nutraceuticals in the prevention and treatment of hypertension. J Am Nutraceut Assoc 1:5–70
46.
Ibsen H, Olsen ME, Watchtell K, Borch-Johnsen K, Lindholm LH, Mogensen CE, Dahlöf B, Devereux RB, de Faire U, Fyhrquist F, Julius S, Kjeldsen SE, Lederballe-Pedersen O, Nieminen MS, Omvik P, Oparil S, Wan Y (2005) Reduction in albuminuria translates to reduction in cardiovascular events in hypertensive patients: losartan intervention for endpoint reduction in hypertension study. Hypertension 45:198–202PubMedCrossRef
47.
Kastelein JJ, van Leuven SI, Burgess L, Evans GW, Kuivenhoven JA, Barter PJ, Revkin JH, Grobbee DE, Riley WA, Shear CL, Duggan WT, Bots ML, RADIANCE 1 Investigators (2007) Effect of torcetrapib on carotid atherosclerosis in familial hypercholesterolemia. N Engl J Med 356:1620–1630PubMedCrossRef
48.
Kawachi I, Golditz GA, Stampfer MJ, Willett WC, Manson JE, Rosner B, Speizer FE, Hennekens CH (1994) Smoking cessation and time course of decreased risk of coronary heart disease in middle-aged women. Arch Intern Med 145:169–175CrossRef
49.
Kjeldsen SE, Kolloch RE, Leonetti G, Mallion JM, Zanchetti A, Elmfeldt D, Warnold I, Hansson L. (2000) Influence of gender and age on preventing cardiovascular disease by antihypertensive treatment and acetylsalicylic acid. The HOT study. Hypertension optimal treatment. J Hypertens 18:629–642PubMed
50.
Kunz R, Friedrich C, Wolbers M, Mann JF (2008) Meta-analysis: effect of monotherapy and combination therapy with inhibitors of the renin-angiotensin system on proteinuria in renal disease. Ann Intern Med 148:30–48PubMed
51.
Leventhal H, Cameron L (1987) Behavioral theories and the problem of compliance. Patient Educ Couns 10:117–138CrossRef
52.
Look AHEAD Research Group (2007) Reduction in weight and cardiovascular disease risk factors in individuals with type 2 diabetes: one-year results of the look AHEAD trial. Diab Care 30:1374–1383CrossRef
53.
Mancia G, De Backer G, Dominiczak A, Cifkova R, Fagard R, Germano G, Grassi G, Heagerty AM, Kjeldsen SE, Laurent S, Narkiewicz K, Ruilope L, Rynkiewicz A, Schmieder RE, Boudier HA, Zanchetti A, Vahanian A, Camm J, De Caterina R, Dean V, Dickstein K, Filippatos G, Funck-Brentano C, Hellemans I, Kristensen SD, McGregor K, Sechtem U, Silber S, Tendera M, Widimsky P, Zamorano JL, Erdine S, Kiowski W, Agabiti-Rosei E, Ambrosioni E, Lindholm LH, Viigimaa M, Adamopoulos S, Agabiti-Rosei E, Ambrosioni E, Bertomeu V, Clement D, Erdine S, Farsang C, Gaita D, Lip G, Mallion JM, Manolis AJ, Nilsson PM, O’Brien E, Ponikowski P, Redon J, Ruschitzka F, Tamargo J, van Zwieten P, Waeber B, Williams B, Management of Arterial Hypertension of the European Society of Hypertension, European Society of Cardiology (2007) 2007 guidelines for the management of arterial hypertension: the task force for the management of arterial hypertension of the European society of hypertension (ESH) and of the European society of cardiology (ESC). J Hypertens 25:1105–1187PubMedCrossRef
54.
Mancia G, Volpe R, Boros S, Ilardi M, Giannattasio C (2004) Cardiovascular risk profile and blood pressure control in Italian hypertensive patients under specialist care. J Hypertens 22:51–57PubMedCrossRef
55.
Matchar DB, McCrory DC, Orlando LA, Patel MR, Patel UD, Patwardhan MB, Powers B, Samsa GP, Gray RN (2008) Systematic review: comparative effectiveness of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers for treating essential hypertension. Ann Intern Med 148:16–29PubMed
56.
Mazzuca SA (1982) Does patient education in chronic disease have therapeutic value? J Chron Dis 35:521–529PubMedCrossRef
57.
Medications and older people. FDA consumer magazine, September–October 1997 issue; (Pub no. FDA 03-1315C). Revised 2003
58.
Morris CD, Carson S (2003) Routine vitamin supplementation to prevent cardiovascular disease: a summary of the evidence for the U.S. Preventive Services Task Force. Ann Intern Med 139:56–70PubMed
59.
National Council on Patient Information, Education (August 2007) Enhancing prescription medicine adherence: a national action plan. NCPIE
60.
Nissen SE, Tardif JC, Nicholls SJ, Revkin JH, Shear CL, Duggan WT, Ruzyllo W, Bachinsky WB, Lasala GP, Tuzcu EM, ILLUSTRATE Investigators (2007) Effect of torcetrapib on the progression of coronary atherosclerosis. N Engl J Med 356:1304–1316PubMedCrossRef
61.
Olsen MH, Watchtell K, Bella JN, Palmieri V, Gerdts E, Smith G, Nieminen MS, Dahlöf B, Ibsen H, Devereux RB (2004) Albuminuria predicts cardiovascular events independently of left ventricular mass in hypertension: a LIFE substudy. J Hum Hypertens 8:453–459CrossRef
62.
ONTARGET Investigators, Yusuf S, Teo KK, Pogue J, Dyal L, Copland I, Schumacher H, Dagenais G, Sleight P, Anderson C (2008) Telmisartan, ramipril, or both in patients at high risk of vascular events. N Engl J Med 358:1547–1559PubMedCrossRef
63.
64.
Pais P, Pogue J, Gerstein H, Zachariah E, Savitha D, Jayprakash S, Nayak PR, Yusuf S (1996) Risk factors for acute myocardial infarction in Indians: a case-control study. Lancet 348:358–363PubMedCrossRef
65.
66.
Prochaska JO (1992) Strong and weak principles for progressing from precontemplation to action. Health Psychol 13:47–51CrossRef
67.
Prochaska JO, DiClemente CC, Norcross JC (1992) In search of how people change. Applications to addictive behaviors. Am Psychol 47:1102–1114PubMedCrossRef
68.
PROGRESS Collaborative Group (2001) Randomised trial of a perindopril based blood-pressure-lowering regimen among 6,105 individuals with previous stroke or transient ischaemic attack. Lancet 358:1033–1041CrossRef
69.
Rosendorff C, Black HR, Cannon CP, Gersh BJ, Gore J, Izzo JL Jr, Kaplan NM, O’Connor CM, O’Gara PT, Oparil S, American Heart Association Council for High Blood Pressure Research, American Heart Association Council on Clinical Cardiology, American Heart Association Council on Epidemiology and Prevention (2007) Treatment of hypertension in the prevention and management of ischemic heart disease: a scientific statement from the American Heart Association Council for high blood pressure research and the councils on clinical cardiology and epidemiology and prevention. Circulation 115:2761–2788
70.
71.
Schmieder RE, Schrader J, Zidek W, Tebbe U, Paar WD, Bramlage P, Pittrow D, Böhm M (2007) Low-grade albuminuria and cardiovascular risk. What is the evidence? Clin Res Cardiol 96:247–257PubMedCrossRef
72.
Schrader J, Luders S, Kulschewski A, Hammersen F, Plate K, Berger J, Zidek W, Dominiak P, Diener HC, MOSES Study Group (2005) Morbidity and mortality after stroke, eprosartan compared with nitrendipine for secondary prevention: principal results of a prospective randomized controlled study (MOSES). Stroke 36:1218–1226PubMedCrossRef
73.
Snow V, Aronson MD, Hornbake ER, Mottur-Pilson C, Weiss KB, Clinical Efficacy Assessment Subcommittee of the American College of Physicians (2004) Lipid control in the management of type 2 diabetes mellitus. Ann Intern Med 140:644–649PubMed
74.
Stefanick ML, Mackey S, Sheehan M, Ellsworth N, Haskell WL, Wood PD (1998) Effects of diet and exercise in men and postmenopausal women with low levels of HDL cholesterol and high levels of LDL cholesterol. N Engl J Med 339:12–20PubMedCrossRef
75.
Tabor PA, Lopez DA (2004) Comply with us: improving medication adherence. J Pharm Pract 17:167–181CrossRef
76.
Tanasescu M, Leitzmann MF, Rimm EB, Hu FB (2003) Physical activity in relation to cardiovascular disease and total mortality among men with type 2 diabetes. Circulation 107:2435–2439PubMedCrossRef
77.
Teo K, Yusuf S, Sleight P, Anderson C, Mookadam F, Ramos B, Hilbrich L, Pogue J, Schumacher H, ONTARGET/TRANSCEND Investigators (2004) Rationale, design, and baseline characteristics of 2 large, simple, randomized trials evaluating telmisartan, ramipril, and their combination in high-risk patients: the ongoing Telmisartan alone and in combination with ramipril global endpoint trial/telmisartan randomized assessment study in ACE intolerant subjects with cardiovascular disease. Am Heart J 148:52–61
78.
The Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) Investigators (2006) High-dose atorvastatin after stroke or transient ischemic attack. N Engl J Med 355:549–559CrossRef
79.
The Warfarin Antiplatelet Vascular Evaluation Trial Investigators (2007) Oral anticoagulant and antiplatelet therapy and peripheral arterial disease. N Engl J Med 357:217–227CrossRef
80.
Tuomilehto J, Lindström J, Erikkson JG, Valle TT, Hämäläinen H, Ilanne-Parikka P, Keinänen-Kiukaanniemi S, Laakso M, Louheranta A, Rastas M, Salminen V, Uusitupa M, Finnish Diabetes Prevention Study Group (2001) Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med 344:1343–1350PubMedCrossRef
81.
Unger T, Stoppelhaar M (2007) Rationale for double renin-angiotensin-aldosterone system blockade. Am J Cardiol 100(3A):25J–31JPubMedCrossRef
82.
Vickrey BG, Rector TS, Wickstrom SL, Guzy PM, Sloss EM, Gorelick PB, Garber S, McCaffrey DF, Dake MD, Levin RA (2002) Occurrence of secondary ischemic events among persons with atherosclerotic vascular disease. Stroke 33:901–906PubMedCrossRef
83.
Vivancos-Mora J, Gil-Nunez AC (2005) Lipids and stroke: the opportunity of lipid-lowering treatment. Cerebrovasc Dis 20(Suppl 2):53–67PubMedCrossRef
84.
Weimar C, Goertler M, Rother J, Ringelstein EB, Darius H, Nabavi DG, Kim IH, Theobald K, Diener HC (2007) Systemic risk score evaluation in ischemic stroke patients (SCALA) : a prospective cross sectional study in 85 German stroke units. J Neurol 254:1562–1568PubMedCrossRef
85.
Yusuf S, Hawken S, Ounpuu S, Dans T, Avezum A, Lanas F, McQueen M, Budaj A, Pais P, Varigos J, Lisheng L, INTERHEART Study Investigators (2004) Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet 364:937–952PubMedCrossRef
86.
Yusuf S, Reddy S, Ôunpuu S, Anand S (2001) Global burden of cardiovascular diseases, part II: variations in cardiovascular disease by specific ethnic groups and geographic regions and prevention strategies. Circulation 104:2855–2864PubMedCrossRef
87.
Zanchetti A, Hansson L, Dahlöf B, Julius S, Ménard J, Warnold I, Wedel H, HOT Study Group (2002) Benefit and harm of low-dose aspirin in well-treated hypertensives at different baseline cardiovascular risk. J Hypertens 20:2301–2307PubMedCrossRef
Metadaten
Titel
Cardiovascular protection for all individuals at high risk: evidence-based best practice
verfasst von
George Bakris
Michael Böhm
Gilles Dagenais
Hans-Christoph Diener
Toshiro Fujita
Philip Gorelick
Sverre Erik Kjeldsen
Markku Laakso
Giuseppe Mancia
Bertram Pitt
Arya Sharma
Peter Sleight
Koon Teo
Thomas Unger
Michael Weber
Bryan Williams
Faiez Zannad
Publikationsdatum
01.10.2008
Verlag
D. Steinkopff-Verlag
Erschienen in
Clinical Research in Cardiology / Ausgabe 10/2008
Print ISSN: 1861-0684
Elektronische ISSN: 1861-0692
DOI
https://doi.org/10.1007/s00392-008-0713-2

Weitere Artikel der Ausgabe 10/2008

Clinical Research in Cardiology 10/2008 Zur Ausgabe

CLINICAL CORRESPONDENCE

Renin-dependent hypertension due to renal angiodysplasia

ORIGINAL PAPER

Impact of pioglitazone on coronary endothelial function in non-diabetic patients with coronary artery disease

CLINICAL CORRESPONDENCE

Acute myocardial infarction associated with use of herbal medication

ORIGINAL PAPER

Two year follow-up after treatment of coronary in-stent restenosis with a paclitaxel-coated balloon catheter

ORIGINAL PAPER

Characterization of patients with acute chest pain using cardiac magnetic resonance imaging

CLINICAL CORRESPONDENCE

Immunoadsorption in a 40 year old man with dilated cardiomyopathy and underlying active myocarditis

Neu im Fachgebiet Kardiologie

Nach Herzinfarkt mit Typ-1-Diabetes schlechtere Karten als mit Typ 2?

29.05.2024 Herzinfarkt Nachrichten

Bei Menschen mit Typ-2-Diabetes sind die Chancen, einen Myokardinfarkt zu überleben, in den letzten 15 Jahren deutlich gestiegen – nicht jedoch bei Betroffenen mit Typ 1.

Erhöhtes Risiko fürs Herz unter Checkpointhemmer-Therapie

28.05.2024 Nebenwirkungen der Krebstherapie Nachrichten

Kardiotoxische Nebenwirkungen einer Therapie mit Immuncheckpointhemmern mögen selten sein – wenn sie aber auftreten, wird es für Patienten oft lebensgefährlich. Voruntersuchung und Monitoring sind daher obligat.

GLP-1-Agonisten können Fortschreiten diabetischer Retinopathie begünstigen

24.05.2024 Diabetische Retinopathie Nachrichten

Möglicherweise hängt es von der Art der Diabetesmedikamente ab, wie hoch das Risiko der Betroffenen ist, dass sich sehkraftgefährdende Komplikationen verschlimmern.

TAVI versus Klappenchirurgie: Neue Vergleichsstudie sorgt für Erstaunen

21.05.2024 TAVI Nachrichten

Bei schwerer Aortenstenose und obstruktiver KHK empfehlen die Leitlinien derzeit eine chirurgische Kombi-Behandlung aus Klappenersatz plus Bypass-OP. Diese Empfehlung wird allerdings jetzt durch eine aktuelle Studie infrage gestellt – mit überraschender Deutlichkeit.

Update Kardiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen